Zealand Pharma A/S (OTCMKTS:ZLDPF) Rating Lowered to Hold at Zacks Research

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.

ZLDPF has been the subject of several other reports. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $36.75 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. Zealand Pharma A/S has a fifty-two week low of $33.08 and a fifty-two week high of $83.12. The stock has a market cap of $2.63 billion, a PE ratio of 6.09 and a beta of 0.99. The firm’s fifty day moving average price is $38.85 and its two-hundred day moving average price is $46.81.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.